1. Stanton, R . Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis 2014; 63(2, Suppl. 2): S3–S21.
Google Scholar | Crossref2. Persson, F, Rossing, P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl 2018; 8: 2–7.
Google Scholar | Crossref3. Colhoun, HM, Marcovecchio, ML. Biomarkers of diabetic kidney disease. Diabetologia 2018; 61: 996–1011.
Google Scholar | Crossref | Medline4. Said, S, Nasr, S. Silent diabetic nephropathy. Kidney Int 2016; 90: 24–26.
Google Scholar | Crossref | Medline5. Bjornstad, P, Cherney, D, Maahs, D. Update on estimation of kidney function in diabetic kidney disease. Curr Diab Rep 2015; 15: 57.
Google Scholar | Crossref | Medline6. Pena, M, Mischak, H, Heerspink, H. Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia 2016; 59: 1819–1831.
Google Scholar | Crossref | Medline7. Al Shawaf, E, Abu-Farha, M, Devarajan, S, et al. ANGPTL4: a predictive marker for diabetic nephropathy. J Diabetes Res 2019; 2019: 4943191.
Google Scholar | Crossref | Medline8. Li, A, Yi, B, Liu, Y, et al. Urinary NGAL and RBP are biomarkers of normoalbuminuric renal insufficiency in type 2 diabetes mellitus. J Immunol Res 2019; 2019: 5063089.
Google Scholar | Crossref | Medline9. Kaul, A, Behera, M, Rai, M, et al. Neutrophil gelatinase-associated lipocalin: as a predictor of early diabetic nephropathy in type 2 diabetes mellitus. Indian J Nephrol 2018; 28: 53–60.
Google Scholar | Crossref | Medline10. Kim, S, Jeong, T, Lee, W, et al. Plasma neutrophil gelatinase-associated lipocalin as a marker of tubular damage in diabetic nephropathy. Ann Lab Med 2018; 38: 524–529.
Google Scholar | Crossref | Medline11. Fawzy, M, Abu AlSel, BT. Assessment of vitamin D-binding protein and early prediction of nephropathy in type 2 Saudi diabetic patients. J Diabetes Res 2018; 2018: 8517929.
Google Scholar | Crossref | Medline12. Gohda, T, Kamei, N, Koshida, T, et al. Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease. J Diabetes Investig 2019; 11: 435–440.
Google Scholar | Crossref | Medline13. Khan, FA, Fatima, SS, Khan, GM, et al. Evaluation of kidney injury molecule-1 as a disease progression biomarker in diabetic nephropathy. Pak J Med Sci 2019; 35: 992–996.
Google Scholar | Medline14. Satirapoj, B, Dispan, R, Radinahamed, P, et al. Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease. BMC Nephrol 2018; 19: 246.
Google Scholar | Crossref | Medline15. Fountoulakis, N, Maltese, G, Gnudi, L, et al. Reduced levels of anti-ageing hormone Klotho predict renal function decline in type 2 diabetes. J Clin Endocrinol Metab 2018; 103: 2026–2032.
Google Scholar | Crossref | Medline16. Bob, F, Schiller, A, Timar, R, et al. Rapid decline of kidney function in diabetic kidney disease is associated with high soluble Klotho levels. Nefrologia 2019; 39: 250–257.
Google Scholar | Crossref | Medline17. Doi, T, Moriya, T, Fujita, Y, et al. Urinary IgG4 and Smad1 are specific biomarkers for renal structural and functional changes in early stages of diabetic nephropathy. Diabetes 2018; 67: 986–993.
Google Scholar | Crossref | Medline18. Akour, A, Kasabri, V, Bulatova, N, et al. Urinary megalin in association with progression factors of diabetic nephropathy. Bratisl Lek Listy 2019; 120: 532–535.
Google Scholar | Medline19. Yamakado, S, Cho, H, Inada, M, et al. Urinary adiponectin as a new diagnostic index for chronic kidney disease due to diabetic nephropathy. BMJ Open Diabetes Res Care 2019; 7: e000661.
Google Scholar | Crossref | Medline20. Bjornstad, P, Pyle, L, Kinney, G, et al. Adiponectin is associated with early diabetic kidney disease in adults with type 1 diabetes: a Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. J Diabetes Complications 2017; 31: 369–374.
Google Scholar | Crossref | Medline21. Li, R, Zhang, L, Zhang, S, et al. Levels and clinical significances of glypican-5 in urine of type 2 diabetic nephropathy cases. Iran J Kidney Dis 2019; 13: 173–181.
Google Scholar | Medline22. Jiang, X, Zhang, Q, Wang, H, et al. Associations of urinary, glomerular, and tubular markers with the development of diabetic kidney disease in type 2 diabetes patients. J Clin Lab Anal 2017; 32: e22191.
Google Scholar23. Currie, G, von Scholten, B, Mary, S, et al. Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. Cardiovasc Diabetol 2018; 17: 50.
Google Scholar | Crossref | Medline24. Heinzel, A, Kammer, M, Mayer, G, et al. Validation of plasma biomarker candidates for the prediction of eGFR decline in patients with type 2 diabetes. Diabetes Care 2018; 41: 1947–1954.
Google Scholar | Crossref | Medline25. Nowak, N, Skupien, J, Smiles, A, et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int 2018; 93: 1198–1206.
Google Scholar | Crossref | Medline26. Colombo, M, Looker, H, Farran, B, et al. Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. Diabetologia 2018; 62: 156–168.
Google Scholar | Crossref | Medline27. Koliwad, S, Gray, N, Wang, JC. Angiopoietin-like 4 (Angptl4): a glucocorticoid-dependent gatekeeper of fatty acid flux during fasting. Adipocyte 2012; 1: 182–187.
Google Scholar | Crossref | Medline28. Li, L, Dong, M, Wang, XG. The implication and significance of beta 2 microglobulin: a conservative multifunctional regulator. Chin Med J 2016; 129: 448–455.
Google Scholar | Crossref | Medline29. Lin, Y, Martin, J, Gruendler, C, et al. A novel link between the proteasome pathway and the signal transduction pathway of the bone morphogenetic proteins (BMPs). BMC Cell Biol 2002; 3: 15.
Google Scholar | Crossref | Medline30. Thway, K, Selfe, J, Shipley, J. GPC5 (glypican 5). Atlas Genet Cytogenet Oncol Haematol 2011; 15: 557–559.
Google Scholar31. Deshmane, SL, Kremlev, S, Amini, S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313–326.
Google Scholar | Crossref | Medline32. Achari, AE, Jain, SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci 2017; 18: 1321.
Google Scholar | Crossref | Medline33. Soni, SS, Cruz, D, Bobek, I, et al. NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol 2010; 42: 141–150.
Google Scholar | Crossref | Medline34. Rozmus, D, Ciesielska, A, Płomiński, J, et al. Vitamin D binding protein (VDBP) and its gene polymorphisms-the risk of malignant tumors and other diseases. Int J Mol Sci 2020; 21: 7822.
Google Scholar | Crossref35. De, S, Kuwahara, S, Saito, A. The endocytic receptor megalin and its associated proteins in proximal tubule epithelial cells. Membranes 2014; 4: 333–355.
Google Scholar | Crossref | Medline36. Xu, Y, Sun, Z. Molecular basis of Klotho: from gene to function in aging. Endocr Rev 2015; 36: 174–193.
Google Scholar | Crossref | Medline37. Mussap, M, Noto, A, Fanos, V, et al. Emerging biomarkers and metabolomics for assessing toxic nephropathy and acute kidney injury (AKI) in neonatology. Biomed Res Int 2014; 2014: 602526.
Google Scholar | Crossref | Medline38. Phan, V, Brophy, P, Fleming, G. Chapter 39. Acute renal failure: prevention, causes, and investigation. In: Geary, DF, Schaefer, F (eds) Comprehensive pediatric nephrology. Philadelphia, PA: Elsevier, 2008, pp. 607–627.
Google Scholar | Crossref39. Bouillon, R . The vitamin D binding protein DBP. In: Feldman, D, Pike, JW, Adams, JS (eds) Vitamin D. San Diego, CA: Academic Press, 2011, pp. 57–72.
Google Scholar | Crossref40. Tian, XQ, Zhao, LM, Ge, JP, et al. Elevated urinary level of vitamin D-binding protein as a novel biomarker for diabetic nephropathy. Exp Ther Med 2014; 7: 411–416.
Google Scholar | Crossref | Medline41. Anadón, A, Castellano, V, Martínez-Larrañaga, M. Biomarkers in drug safety evaluation. In: Gupta, RC (ed.) Biomarkers in toxicology. Philadelphia, PA: Elsevier, 2014, pp. 923–945.
Google Scholar | Crossref42. Ogasawara, S, Hosojima, M, Kaseda, R, et al. Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes. Diabetes Care 2012; 35: 1112–1118.
Google Scholar | Crossref | Medline43. Xiang, A, Ekinci, E, MacIsaac, R. Inflammatory proteins in diabetic kidney disease—potential as biomarkers and therapeutic targets. Ann Transl Med 2019; 7(Suppl. 6): S243.
Google Scholar | Crossref44. Kim, M, Tam, F. Urinary monocyte chemoattractant protein-1 in renal disease. Clin Chim Acta 2011; 412: 2022–2030.
Google Scholar | Crossref | Medline45. Okamoto, K, Honda, K, Doi, K, et al. Glypican-5 increases susceptibility to nephrotic damage in diabetic kidney. Am J Pathol 2015; 185: 1889–1898.
Google Scholar | Crossref | Medline46. Abe, H, Matsubara, T, Iehara, N, et al. Type IV collagen is transcriptionally regulated by smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 2004; 279: 14201–14206.
Google Scholar | Crossref | Medline47. Clement, L, Avila-Casado, C, Macé, C, et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 2010; 17: 117–122.
Google Scholar | Crossref | Medline48. Pavik, I, Jaeger, P, Ebner, L, et al. Secreted Klotho and FGF23 in chronic kidney disease stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 2013; 28: 352–359.
Google Scholar | Crossref | Medline49. Schrauben, SJ, Shou, H, Zhang, X, et al. Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Soc Nephrol 2021; 32: 115–126.
Google Scholar | Crossref | Medline50. Pontillo, C, Zhang, ZY, Schanstra, JP, et al. Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker. Kidney Int Rep 2017; 2: 1066–1075.
Google Scholar | Crossref | Medline51. Puthumana, J, Thiessen-Philbrook, H, Xu, L, et al. Biomarkers of inflammation and repair in kidney disease progression. J Clin Invest 2021; 131: e139927.
Google Scholar | Crossref | Medline52. Perco, P, Pena, M, Heerspink, H, et al. Multimarker panels in diabetic kidney disease: the way to improved clinical trial design and clinical practice. Kidney Int Rep 2019; 4: 212–221.
Google Scholar | Crossref | Medline53. Lindhardt, M, Persson, F, Zürbig, P, et al. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial Transplant 2016; 32: 18